What is Baxter International Inc?
, through its subsidiaries, provides a portfolio of healthcare products in the United States.
BAX · Verdict
Limited reward · elevated risk
BAX's standout is volatility; profitability and valuation weigh on the picture.
Based on 88% data coverage
BAX · Verdict
Above average
-9% net margin · -14% ROE
P/E 9.4× · PEG 36.68
Rev +3.8% CAGR · earnings -26.7%
Net debt/EBITDA 10.5×
3% free-cash-flow margin
Model-based scoring. For information only — not financial advice.
, through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 8.72B.
The scoring profile indicates weak reward characteristics across most factors, including momentum and size. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.